pipette
ESEspañol

NECTIN4 defines a subtype-dependent tumor state coupling enfortumab vedotin targetability to antitumor immunity in bladder cancer

K. Nishimura, R. Maenosono, T. Owari, M. Sakamoto, T. Nishino, K. Hirosuna, T. Tsujino, T. Izumi-Tamura, Y. Yoshikawa, M. Azuma, S. Inoue, A. Kawachi, A. Ishida, K. Nishimori, J. Mukohyama, N. Shinohara, M. Sakumoto, M. Amisaki, K. Okuyama, M. Ishida, M. Ajiro, Y. Hirose, Y. Suzuki, H. Nishikawa, H. Azuma, F. L. F. Carvalho, A. S. Kibel, L. Jia, S. Koyama, T. Yoshino, K. Komura, A. Yoshimi

PreprintReal-world use

In the authors' words

NECTIN4 is the target of enfortumab vedotin (EV), but its biological role in bladder cancer (BC) and its relationship to EV plus PD-1 blockade remain unclear. Integrating clinical multi-omics, spatial and single-cell immune profiling, and experimental models, we identify NECTIN4 as a subtype-dependent determinant of tumor state and antitumor immunity. In basal BC cells, NECTIN4 suppressed inflammatory and mesenchymal programs. Consistently, NECTIN4-high basal/squamous muscle-invasive BCs showed favorable survival, higher checkpoint inhibitor response rates, and a coordinated CD8+ T cell-inflamed microenvironment with no comparable associations in luminal papillary tumors. In orthotopic models, murine Nectin4 promoted CD8+ T cell-dependent tumor control, whereas human NECTIN4 conferred EV sensitivity. EV also attenuated NECTIN4-dependent TIGIT binding. Conversely, NECTIN4-low models were preferentially sensitive to HDAC inhibition. NECTIN4 therefore couples antibody-drug conjugate targetability to a subtype-specific tumor-immune state permissive for checkpoint blockade, whereas the NECTIN4-low state defines a distinct inflammatory-mesenchymal state with an alternative therapeutic vulnerability.

Main resultThe abstract does not state a limitation.

Appeared: Saturday, October 10. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.07.757381